Merck (MRK)
125.78
+0.55 (0.44%)
Upcoming Events
Latest Headlines
MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour
April 17, 2024 8:00 AM - BizWire
MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing
April 16, 2024 8:03 AM - BizWire
Form ARS Merck & Co., Inc. For: Dec 31
April 11, 2024 4:13 PM - SEC Filing
Form DEFA14A Merck & Co., Inc.
April 11, 2024 4:11 PM - SEC Filing
Form DEF 14A Merck & Co., Inc. For: May 28
April 11, 2024 4:09 PM - SEC Filing
Form 10-K/A Merck & Co., Inc. For: Dec 31
April 11, 2024 4:06 PM - SEC Filing
Form 3 Merck & Co., Inc. For: Apr 01 Filed by: Larson Betty D
April 8, 2024 1:56 PM - SEC Filing
Merck (MRK) PT Raised to $143 at Berenberg
April 8, 2024 4:54 AM - StreetInsider
Merck (MRK) Initiates Phase 3 Clinical Trial of MK-1084
April 4, 2024 6:45 AM - StreetInsider
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metasta
April 4, 2024 6:45 AM - BizWire
Daiichi Sankyo and Merck (MRK) Announce REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
April 3, 2024 8:04 AM - StreetInsider
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
April 3, 2024 8:00 AM - BizWire
Form PX14A6G Merck & Co., Inc. Filed by: Inspire Investing, LLC
April 1, 2024 5:17 PM - SEC Filing
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
April 1, 2024 6:45 AM - BizWire
Form 4 Merck & Co., Inc. For: Mar 28 Filed by: WENDELL PETER C
March 29, 2024 4:19 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Mar 28 Filed by: Seidman Christine E
March 29, 2024 4:17 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Mar 28 Filed by: GLOCER THOMAS H
March 29, 2024 4:14 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Mar 28 Filed by: Coe Mary Ellen
March 29, 2024 4:13 PM - SEC Filing
Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy for NSCLC
March 28, 2024 6:46 AM - StreetInsider
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Ca
March 28, 2024 6:45 AM - BizWire
Form PX14A6G Merck & Co., Inc. Filed by: Bowyer Research, Inc.
March 28, 2024 6:07 AM - SEC Filing
Merck (MRK) PT Raised to $142 at Truist Securities
March 27, 2024 8:53 AM - StreetInsider
Midday movers: GameStop falls; Merck, Robinhood and Moderna rise
March 27, 2024 8:17 AM - StreetInsider
Merck (MRK) PT Raised to $145 at Jefferies, 'modeling a strong launch out of the gate' for Winrevair
March 27, 2024 7:53 AM - StreetInsider
Merck (MRK) PT Raised to $135 at Wells Fargo
March 27, 2024 6:24 AM - StreetInsider
Merck hits record high after FDA approves lung disease drug
March 27, 2024 6:06 AM - StreetInsider
Truist Securities Reiterates Buy Rating on Merck (MRK)
March 27, 2024 4:44 AM - StreetInsider
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
March 26, 2024 6:21 PM - BizWire
US FDA approves Merck's therapy for rare lung condition
March 26, 2024 5:11 PM - StreetInsider
After-hours movers: Merck, GameStop, Shockwave Medical, and more
March 26, 2024 5:00 PM - StreetInsider
Merck's (MRK) Sotatercept Approved by FDA for High Blood Pressure
March 26, 2024 4:55 PM - StreetInsider
Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region
March 26, 2024 9:33 AM - StreetInsider
Merck (MRK) Provides Update on Phase 3 KEYLYNK-006 Trial of KEYTRUDA Plus Maintenance LYNPARZA
March 21, 2024 6:45 AM - StreetInsider
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Can
March 21, 2024 6:45 AM - BizWire
MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea
March 20, 2024 11:03 AM - BizWire
Merck (MRK) Files for Debt Offering
March 19, 2024 4:33 PM - StreetInsider
Form S-3ASR Merck & Co., Inc.
March 19, 2024 4:32 PM - SEC Filing
Form S-3ASR Merck & Co., Inc.
March 19, 2024 4:31 PM - SEC Filing
Merck (MRK) Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
March 19, 2024 9:02 AM - StreetInsider
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
March 19, 2024 9:00 AM - BizWire
Top pharma stocks to own in 2024 – Citi
March 17, 2024 8:00 PM - StreetInsider
FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
March 15, 2024 4:23 PM - PR NewsWire
Merck (MRK) Reports KEYTRUDA Plus Chemoradiotherapy Significantly Improved OS Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
March 15, 2024 6:45 AM - StreetInsider
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Can
March 15, 2024 6:45 AM - BizWire
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
March 13, 2024 3:00 AM - BizWire
IDEAYA Biosciences (IDYA) to Evaluate IDE161 in Combination with KEYTRUDA
March 12, 2024 6:01 AM - StreetInsider
Societe Generale Downgrades Merck (MRK) to Sell
March 11, 2024 12:47 PM - StreetInsider
Moderna (MRNA) Trades at High, Up 9%
March 11, 2024 9:54 AM - StreetInsider
Merck (MRK) Completes Acquisition of Harpoon Therapeutics
March 11, 2024 8:15 AM - StreetInsider
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
March 11, 2024 8:15 AM - BizWire
Gilead Sciences (GILD) and Merck (MRK) Report Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
March 6, 2024 10:25 AM - StreetInsider
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
March 6, 2024 10:25 AM - BizWire
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 5, 2024 8:30 AM - StreetInsider
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference
March 5, 2024 6:45 AM - BizWire
Merck to Participate in the Leerink Partners Global Biopharma Conference 2024
March 4, 2024 6:45 AM - BizWire
Goldman Makes New Monthly Adjustments to Directors Cut Names, 'inclusion on this list is not a stock rating'
March 1, 2024 5:09 AM - StreetInsider
EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits
February 29, 2024 8:00 AM - BizWire
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 7:00 AM - BizWire
Merck to Participate in the TD Cowen 44th Annual Health Care Conference
February 27, 2024 6:45 AM - BizWire
Form 10-K Merck & Co., Inc. For: Dec 31
February 26, 2024 4:27 PM - SEC Filing
Merck (MRK) Reports Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectabl
February 23, 2024 6:23 AM - StreetInsider
Merck's (MRK) Keytruda receives positive CHMP opinion to expand Keytruda for certain non-small cell lung carcinoma
February 23, 2024 6:21 AM - StreetInsider
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment
February 23, 2024 6:20 AM - BizWire
Merck (MRK) PT Raised to $140 at Berenberg
February 21, 2024 5:14 AM - StreetInsider
Form 8-K Merck & Co., Inc. For: Feb 15
February 20, 2024 4:15 PM - SEC Filing
Merck (MRK) Granted FDA Priority Review for KEYTRUDA Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
February 20, 2024 6:45 AM - StreetInsider
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
February 20, 2024 6:45 AM - BizWire
Form 4 Merck & Co., Inc. For: Feb 14 Filed by: Litchfield Caroline
February 15, 2024 4:04 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Feb 13 Filed by: Davis Robert M
February 15, 2024 4:02 PM - SEC Filing
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
February 15, 2024 8:45 AM - StreetInsider
Form 144 Merck & Co., Inc. Filed by: Karachun Rita A
February 14, 2024 4:41 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Litchfield Caroline
February 14, 2024 4:31 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Davis Robert M
February 14, 2024 4:25 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Feb 13 Filed by: Romanelli Joseph
February 14, 2024 4:06 PM - SEC Filing
Form SC 13G/A Merck & Co., Inc. Filed by: VANGUARD GROUP INC
February 13, 2024 4:56 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Romanelli Joseph
February 13, 2024 4:50 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Davis Robert M
February 13, 2024 4:49 PM - SEC Filing
Pharmaceutical group's lawsuit over Medicare drug price program dismissed
February 12, 2024 10:07 PM - StreetInsider
Form 4 Merck & Co., Inc. For: Feb 09 Filed by: Li Dean Y
February 12, 2024 4:04 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Li Dean Y
February 9, 2024 4:07 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Feb 07 Filed by: Williams David Michael
February 8, 2024 4:05 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Williams David Michael
February 7, 2024 4:09 PM - SEC Filing
Merck (MRK) PT Raised to $140 at Argus
February 7, 2024 7:39 AM - StreetInsider
Form 4 Merck & Co., Inc. For: Feb 02 Filed by: Oosthuizen Johannes Jacobus
February 5, 2024 4:02 PM - SEC Filing
Merck Animal Health (MRK) Acquires Elanco’s (ELAN) Aqua Business for $1.3B Cash
February 5, 2024 6:33 AM - StreetInsider
Elanco Announces Sale of Aqua Business for $1.3 Billion
February 5, 2024 6:33 AM - PR NewsWire
Merck Animal Health to Acquire Elanco’s Aqua Business
February 5, 2024 6:33 AM - BizWire
Merck (MRK) PT Raised to $143 at DZ Bank
February 5, 2024 4:16 AM - StreetInsider
Form 144 Merck & Co., Inc. Filed by: Oosthuizen Johannes Jacobus
February 2, 2024 4:36 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Zachary Jennifer
February 2, 2024 4:09 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: MIZELL STEVEN
February 2, 2024 4:09 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Feb 02 Filed by: MIZELL STEVEN
February 2, 2024 4:08 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Feb 02 Filed by: Zachary Jennifer
February 2, 2024 4:06 PM - SEC Filing
Merck (MRK) PT Raised to $130 at Wells Fargo
February 2, 2024 8:08 AM - StreetInsider
Merck (MRK) PT Raised to $148 at UBS
February 2, 2024 7:45 AM - StreetInsider
Merck (MRK) PT Raised to $139 at Truist Securities
February 2, 2024 7:30 AM - StreetInsider
Merck (MRK) PT Raised to $134 at Goldman Sachs
February 2, 2024 4:14 AM - StreetInsider
Merck (MRK) PT Raised to $145 at Barclays
February 2, 2024 3:21 AM - StreetInsider
Merck (MRK) PT Raised to $140 at Jefferies
February 1, 2024 1:24 PM - StreetInsider
US stocks rise ahead of more mega-cap tech earnings
February 1, 2024 11:25 AM - StreetInsider
Merck (MRK) looking at deals up to $15B - CEO
February 1, 2024 9:47 AM - StreetInsider
Midday movers: Ferrari races higher, Qualcomm sputters, and more
February 1, 2024 8:25 AM - StreetInsider
Goldman Sachs just released the list of top stocks to own in February
February 1, 2024 7:00 AM - StreetInsider
Keytruda strength fuels earnings beat for Merck (MRK)
February 1, 2024 6:47 AM - StreetInsider
Form 8-K Merck & Co., Inc. For: Jan 29
February 1, 2024 6:39 AM - SEC Filing
Merck seeks more deals to prepare for Keytruda's revenue decline
February 1, 2024 6:33 AM - StreetInsider
Merck (MRK) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY24 Guidance
February 1, 2024 6:31 AM - StreetInsider
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
February 1, 2024 6:30 AM - BizWire
Merck (MRK) February weekly 121 straddle into quarter results
February 1, 2024 4:25 AM - StreetInsider
Merck (MRK) February weekly option implied volatility into quarter results
January 31, 2024 11:00 AM - StreetInsider
Merck (MRK) February weekly 121 straddle into quarter results
January 31, 2024 5:46 AM - StreetInsider
Merck (MRK) PT Raised to $127 at Morgan Stanley
January 30, 2024 10:52 AM - StreetInsider
Merck (MRK) PT Raised to $130 at Guggenheim
January 29, 2024 6:11 AM - StreetInsider
Merck's (MRK) KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC)
January 29, 2024 5:54 AM - StreetInsider
Merck (MRK) PT Raised to $135 at Deutsche Bank
January 29, 2024 5:39 AM - StreetInsider
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephr
January 27, 2024 10:00 AM - BizWire
Form SC 13G/A Merck & Co., Inc. Filed by: BlackRock Inc.
January 26, 2024 11:51 AM - SEC Filing
Merck (MRK) Reports KEYTRUDA Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothel
January 26, 2024 10:00 AM - StreetInsider
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced
January 26, 2024 10:00 AM - BizWire
Form 4 Merck & Co., Inc. For: Jan 22 Filed by: Oosthuizen Johannes Jacobus
January 24, 2024 4:18 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Jan 22 Filed by: Smart Dalton
January 24, 2024 4:16 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Jan 22 Filed by: Williams David Michael
January 24, 2024 4:15 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Jan 22 Filed by: MIZELL STEVEN
January 24, 2024 4:13 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Jan 22 Filed by: Zachary Jennifer
January 24, 2024 4:12 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Jan 22 Filed by: Li Dean Y
January 24, 2024 4:10 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Jan 22 Filed by: Davis Robert M
January 24, 2024 4:09 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Jan 22 Filed by: DeLuca Richard R.
January 24, 2024 4:07 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Jan 22 Filed by: Chattopadhyay Sanat
January 24, 2024 4:06 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Jan 22 Filed by: Litchfield Caroline
January 24, 2024 4:04 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Jan 22 Filed by: Klobuchar Michael A
January 24, 2024 4:02 PM - SEC Filing
Merck (MRK) PT Raised to $125 at Wells Fargo
January 24, 2024 7:19 AM - StreetInsider
Merck (MRK) Declares $0.77 Quarterly Dividend; 2.6% Yield
January 23, 2024 2:44 PM - StreetInsider
Merck Announces Second-Quarter 2024 Dividend
January 23, 2024 2:44 PM - BizWire
Merck (MRK) PT Raised to $135 at Barclays
January 23, 2024 3:26 AM - StreetInsider
Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
January 22, 2024 5:00 PM - BizWire
Citi Opens Upside Catalyst Watch on Merck (MRK)
January 22, 2024 4:09 AM - StreetInsider
Full Article List
